Archives
-
InstaBlue Protein Stain Solution Protocol
2026-09-19
InstaBlue Protein Stain Solution provides rapid visualization of protein bands in polyacrylamide gels without fixation, washing, or destaining. It is suited to routine protein electrophoresis analysis and mass spectrometry workflows, but laboratories should validate performance for quantitative measurements, long-term gel archiving, or applications requiring fixed gels.
-
5-Azacytidine in Multiple Myeloma: DNA Damage
2026-09-18
The reference study shows that 5-Azacytidine affects multiple myeloma cells through more than DNA demethylation: it activates ATR-associated DNA double-strand break responses and engages both caspase-dependent and caspase-independent apoptosis. Its activity in resistant models and synergy with doxorubicin or bortezomib provide a mechanistic preclinical basis for combination studies, while also highlighting the limits of translating in vitro findings directly to patients.
-
Lipid Peroxidation (MDA) Assay Kit: Ferroptosis Insight
2026-09-18
Learn how the Lipid Peroxidation (MDA) Assay Kit can strengthen ferroptosis and oxidative stress studies. This guide connects MDA measurement with orthogonal readouts, sample controls, and mechanistic interpretation in doxorubicin-induced liver injury.
-
CHIR 99021 trihydrochloride in Organoids
2026-09-17
CHIR 99021 trihydrochloride gives researchers a reversible way to probe GSK-3-dependent control of organoid expansion, differentiation, and metabolic signaling. This workflow connects tunable intestinal organoid design with stem cell, beta-cell, and type 2 diabetes research while emphasizing dose control, washout experiments, and assay-specific validation.
-
PKH26 Red Fluorescent Cell Linker Kit Guide
2026-09-17
The PKH26 Red Fluorescent Cell Linker Kit provides stable red labeling of cell membrane lipid regions for tracing and proliferation-oriented assays in vitro and in vivo. It is intended for membrane labeling, not intracellular targets or non-membrane structures, and exact working conditions should be optimized with appropriate controls.
-
EGF Signaling in 3D Glioblastoma Stemness Assays
2026-09-16
A translational framework for using recombinant human EGF as a controlled perturbation in glioblastoma spheroid assays, while distinguishing proliferation from stem-like behavior and connecting reagent quality to experimental decisions.
-
Trametinib: Mapping MEK Resistance in Melanoma
2026-09-16
Trametinib and GSK1120212 provide precise MEK1/2 inhibition for dissecting MAPK-driven cell-state changes. This article connects pathway pharmacology with multi-omics-informed assay design for studying adaptive resistance, G1 arrest, and apoptosis in melanoma models.
-
Pretomanid Targets Both TB Terminal Oxidases
2026-09-15
The reference study shows that pretomanid inhibits both cytochrome bcc:aa3 and cytochrome bd terminal oxidase branches in Mycobacterium tuberculosis. This dual respiratory mechanism explains synergy with telacebec and supports combination regimens designed to improve bactericidal activity while limiting resistance.
-
Targeted BRD7 Demethylation in Nasopharyngeal Carcinoma
2026-09-15
The reference study shows that hypermethylation of the BRD7 promoter suppresses a tumor-suppressive program in nasopharyngeal carcinoma (NPC). By directing dCas9-TET1 catalytic activity to selected promoter sites, the authors reactivated BRD7 and reduced malignant progression, with combined sgRNA2 and sgRNA5 producing the strongest reported effect.
-
Precision PCR for CRISPR Immunotherapy Translation
2026-09-14
A thought-leadership analysis of how high-fidelity PCR can strengthen translational workflows inspired by bufalin–CRISPR nanomedicine research in colorectal cancer. The article connects immune mechanism, construct integrity, blunt-end cloning, assay reproducibility, and strategic experimental design while positioning 2X HyperFusion™ High-Fidelity Master Mix as an enabling technology rather than a substitute for biological validation.
-
Influenza A NEP Constraints from Mutational Scanning
2026-09-14
A 2025 Cell Reports study used deep mutational scanning to measure the replication effects of more than 1,800 single-amino-acid mutations in influenza A virus nuclear export protein (NEP). The work shows that the apparently disordered N-terminal domain is unusually mutation-tolerant but still influences viral RNA synthesis, host responses, and mammalian adaptation, revealing functional constraints that sequence conservation alone cannot resolve.
-
Ciclesonide B3477 for Reliable Cell Assays
2026-09-13
Learn how Ciclesonide (SKU B3477) can improve experimental control in respiratory cell models by separating prodrug activation, glucocorticoid receptor binding, solvent handling, and biological interpretation. This scenario-driven guide links quantitative product data with practical assay design while clearly distinguishing established respiratory pharmacology from emerging ERAD research.
-
Itraconazole: Mechanism, Biofilm Evidence, and Use
2026-09-12
Itraconazole is a triazole antifungal agent with activity against selected Candida species and important CYP3A4 interaction properties. This article separates direct itraconazole evidence from mechanistic evidence on Candida biofilm resistance and PP2A-regulated autophagy.
-
Paclitaxel (Taxol): Workflow for Cancer Research
2026-09-11
Build more interpretable cancer assays with Paclitaxel (Taxol), from solvent-controlled microtubule stabilization to G2-M profiling and combination studies. A FOXM1-focused reference study adds a practical framework for testing whether pathway suppression can sensitize resistant models to paclitaxel.
-
Ciclesonide Assays: From Prodrug to ERAD Insight
2026-09-11
Ciclesonide provides a powerful model for linking prodrug activation, glucocorticoid receptor binding, and lung-cell pharmacology. This article adds an assay-design framework that distinguishes validated respiratory biology from the emerging ERAD platform reported for desonide-based degraders.